Several brokerages have updated their recommendations and price targets on shares of Relay Therapeutics (NASDAQ: RLAY) in the last few weeks:
- 8/14/2026 – Relay Therapeutics had its price target raised by JPMorgan Chase & Co. from $28.00 to $31.00. They now have an “overweight” rating on the stock.
- 8/10/2026 – Relay Therapeutics had its “market outperform” rating reaffirmed by Citigroup Inc..
- 8/10/2026 – Relay Therapeutics had its price target raised by Citizens Jmp from $21.00 to $26.00. They now have a “market outperform” rating on the stock.
- 8/7/2026 – Relay Therapeutics had its price target raised by Barclays PLC from $27.00 to $30.00. They now have an “overweight” rating on the stock.
- 8/7/2026 – Relay Therapeutics had its “buy” rating reaffirmed by Guggenheim.
- 7/22/2026 – Relay Therapeutics was downgraded by Zacks Research from “hold” to “strong sell”.
- 7/21/2026 – Relay Therapeutics had its price target raised by The Goldman Sachs Group, Inc. from $22.00 to $31.00. They now have a “buy” rating on the stock.
- 7/16/2026 – Relay Therapeutics is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $29.00 price target on the stock.
- 7/16/2026 – Relay Therapeutics is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $29.00 price target on the stock.
- 7/8/2026 – Relay Therapeutics is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $28.00 price target on the stock.
- 7/6/2026 – Relay Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
Insider Activity at Relay Therapeutics
In related news, CFO Thomas Catinazzo sold 187,163 shares of the company’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $16.97, for a total value of $3,176,156.11. Following the completion of the transaction, the chief financial officer directly owned 177,461 shares of the company’s stock, valued at approximately $3,011,513.17. This represents a 51.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Sanjiv Patel sold 48,199 shares of the stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $19.58, for a total value of $943,736.42. Following the transaction, the chief executive officer owned 615,898 shares of the company’s stock, valued at approximately $12,059,282.84. This trade represents a 7.26% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 409,639 shares of company stock worth $7,233,399 over the last ninety days. 5.04% of the stock is owned by corporate insiders.
The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.
See Also
- Five stocks we like better than Relay Therapeutics
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Relay Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relay Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
-inc-logo-1200x675.jpg){kind=logo}